Sugi Predict

Sugi Predict / Compounds / SCHEMBL3208544

SCHEMBL3208544

SCHEMBL3208544

Cc1ccc(NC(=O)Nc2cc(F)cc([C@@H](C)N3CCN(C(=O)O)CC3)c2)cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK10 P53779 5/20 0.40
▸ MAPK8 P45983 4/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.39
▸ SCN5A Q14524 1/20 0.39
▸ SCN9A Q15858 1/20 0.39
▸ KCNQ3 O43525 1/20 0.39
▸ KCNQ2 O43526 1/20 0.39
▸ KDR P35968 2/20 0.39
▸ ACKR3 P25106 1/20 0.38
▸ CSNK1E P49674 1/20 0.38
▸ CYP1A2 P05177 1/20 0.37
▸ DDX3X O00571 1/20 0.37
▸ EPHX2 P34913 1/20 0.36
▸ IDO1 P14902 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ OGA O60502 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3199795 1.00 MAPK10 (0.40) MAPK10MAPK8NPSR1SCN5ASCN9A
SCHEMBL4241824 1.00 MAPK10 (0.40) MAPK10MAPK8NPSR1SCN5ASCN9A
SCHEMBL4243861 0.90 MAPK10 (0.40) MAPK10MAPK8NPSR1KCNQ3KCNQ2
SCHEMBL402275 0.90 MAPK10 (0.40) MAPK10MAPK8NPSR1KCNQ3KCNQ2
SCHEMBL401529 0.90 MAPK10 (0.40) MAPK10MAPK8NPSR1KCNQ3KCNQ2
SCHEMBL4237722 0.89 CHRM2 (0.43) MAPK10MAPK8KDRDDX3XEPHX2
SCHEMBL398919 0.89 CHRM2 (0.43) MAPK10MAPK8KDRDDX3XEPHX2
SCHEMBL402520 0.89 CHRM2 (0.43) MAPK10MAPK8KDRDDX3XEPHX2
SCHEMBL401139 0.87 MAPT (0.44) KDRNPC1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL402787 0.87 MAPT (0.44) KDRNPC1ALDH1A1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220185779-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2022-06-16 — — US disclosed
US-20210198203-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2021-07-01 — — US disclosed
US-10975034-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2021-04-13 — — US disclosed
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2019-11-21 — — US disclosed
US-10385023-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2019-08-20 — — US disclosed
US-20180305316-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2018-10-25 — — US disclosed
US-10035770-B2 Compounds, compositions and methods CYTOKINETICS, INCORPORATED (US) 2018-07-31 — — US disclosed
US-20170267638-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2017-09-21 — — US disclosed
US-9643925-B2 Compounds, compositions and methods CYTOKINETICS, INCORPORATED 2017-05-09 — — US disclosed
US-20160115133-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2016-04-28 — — US disclosed
US-20120172372-A1 Ureas and Their Use in the Treatment of Heart Failure CYTOKINETICS, INC. 2012-07-05 — — US disclosed
US-20100029680-A1 Certain Chemical Entities, Compositions and Methods CYTOKINETICS, INC. 2010-02-04 — — US disclosed
US-20090247544-A1 Certain Chemical Entities, Compositions and Methods CYTOKINETICS, INC. 2009-10-01 — — US disclosed
US-20090099198-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. 2009-04-16 — — US disclosed
US-7507735-B2 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INC. (US) 2009-03-24 — — US disclosed
US-20090036447-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. (US) 2009-02-05 — — US disclosed
US-20070208000-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-09-06 — — US disclosed
US-20070197505-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-08-23 — — US disclosed
US-20070161617-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-07-12 — — US disclosed
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INCORPORATED 2006-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172372-A1 Ureas and Their Use in the Treatment of Heart Failure TNNI3, TNNT2, MYLK2 MAPK10 2342/4885MAPK8 3165/4885NPSR1 4262/4885
US-20070161617-A1 Certain chemical entities, compositions and methods TNNI3, TNNT2, MYLK2 MAPK10 2458/4885MAPK8 3317/4885NPSR1 4682/4885
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate TNNI3, MYLK2, TNNT2 MAPK10 1989/4885MAPK8 2821/4885NPSR1 4567/4885
US-20170267638-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 MAPK10 2521/4885MAPK8 3460/4885NPSR1 4780/4885
US-10385023-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 MAPK10 2521/4885MAPK8 3460/4885NPSR1 4780/4885
US-20220185779-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 MAPK10 2521/4885MAPK8 3460/4885NPSR1 4780/4885
US-20090099198-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 MAPK10 2521/4885MAPK8 3460/4885NPSR1 4780/4885
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 MAPK10 2521/4885MAPK8 3460/4885NPSR1 4780/4885
US-20070208000-A1 Certain chemical entities, compositions and methods TNNI3, TNNT2, MYLK2 MAPK10 2458/4885MAPK8 3317/4885NPSR1 4682/4885
US-20070197505-A1 Certain chemical entities, compositions and methods TNNC1, TNNI3, TNNT2 MAPK10 2706/4885MAPK8 3594/4885NPSR1 3300/4885
US-20160115133-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 MAPK10 2521/4885MAPK8 3460/4885NPSR1 4780/4885
US-10975034-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 MAPK10 2521/4885MAPK8 3460/4885NPSR1 4780/4885
US-10035770-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 MAPK10 2521/4885MAPK8 3460/4885NPSR1 4780/4885
US-20100029680-A1 Certain Chemical Entities, Compositions and Methods TNNI3, TNNT2, MYLK2 MAPK10 2458/4885MAPK8 3317/4885NPSR1 4682/4885
US-20090036447-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 MAPK10 2521/4885MAPK8 3460/4885NPSR1 4780/4885
US-20180305316-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 MAPK10 2521/4885MAPK8 3460/4885NPSR1 4780/4885
US-20210198203-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 MAPK10 2521/4885MAPK8 3460/4885NPSR1 4780/4885
US-20090247544-A1 Certain Chemical Entities, Compositions and Methods TNNC1, TNNI3, TNNT2 MAPK10 2706/4885MAPK8 3594/4885NPSR1 3300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.